Pharmacological administration of CXCL9, but not CXCL10, strongly inhibits collagen deposition in isolated human pulmonary arterial smooth muscle cells (hPASMCs) and ex vivo precision-cut lung slices from end-stage IPF-PH patients [303]. Here, CXCL10 is linked to idiopathic interstitial pneumonia.